AVITA Medical, Inc. RCEL
16.20 USD -1.10 (-6.36%)
At closeNov 12, 2026, 4:16 PM EST
17.23 +1.03 +6.33%
After hours · Nov 12, 4:16 PM ET
16.13 Day range 17.57
3.22 52-week range 18.43
- YTD
- +369.57%
- 1 year
- +328.57%
News
benzinga.com TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $22 TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $20 to $22.
seekingalpha.com AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript AVITA Medical, Inc. ( RCEL ) Shareholder/Analyst Call November 11, 2026 5:00 PM EST Company Participants Cary Vance - President, CEO & Executive Director David OToole - Chief Financial Officer Ben…
zacks.com Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com AVITA Medical, Inc. (RCEL) Q3 2026 Earnings Call Transcript AVITA Medical, Inc. ( RCEL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance -…
globenewswire.com AVITA Medical to Host Investor Webinar Briefing VALENCIA, Calif., Nov. 08, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering…
benzinga.com Lake Street Maintains Buy on AVITA Medical, Raises Price Target to $20 Lake Street analyst Frank Takkinen maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $20.
benzinga.com Texas Roadhouse To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Friday Wall Street analysts adjusted price targets and ratings for BlackLine, GXO Logistics, Karman, Helios, Wendy’s, Applied Optoelectronics and others.
marketbeat.com Avita Medical Q3 Earnings Call Highlights Avita Medical NASDAQ: RCEL raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound…
benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $21 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $15 to $21.
benzinga.com AVITA Medical Q3 2026 Earnings Call Transcript AVITA Medical (NASDAQ:RCEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com AVITA Medical Q3 EPS $(0.20) Beats $(0.22) Estimate, Sales $25.862M Beat $22.200M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 56.52 percent increase over losses of…- benzinga.com AVITA Medical Raises FY2026 Sales Guidance from $86.000M-$89.000M to $92.000M-$94.000M vs $86.850M Est AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $86.000 million-$89.000 million to $92.000 million-$94.000 million vs $86.850 million estimate.
globenewswire.com AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a…
globenewswire.com AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 CMS finalizes nationally published physician valuations; CMS's four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA…
globenewswire.com AVITA Medical to Announce Third Quarter 2026 Financial Results VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering…
benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
benzinga.com AVITA Medical Q2 2026 Earnings Call Transcript On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings…
defenseworld.net Head-To-Head Comparison: Organigram Global (NASDAQ:OGI) versus Avita Medical (NASDAQ:RCEL) Organigram Global (NASDAQ: OGI - Get Free Report) and Avita Medical (NASDAQ: RCEL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two…
seekingalpha.com Leading Indicators For The October Breakout Cycle Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have…
gurufocus.com Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued On October 02, 2026, AVITA Medical Inc (RCEL) shares rose 5.9% to a current price of $12.72, within a 52-week range of $3.22 to $12.76. The stock has shown impr
defenseworld.net NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL NewEdge Advisors LLC grew its position in Avita Medical Inc. (NASDAQ: RCEL) by 71.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned…
seekingalpha.com AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced…
zacks.com All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy? Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com AVITA Medical: Favorable Reimbursements For Skin Wound Care AVITA Medical's reimbursement is now becoming more predictable. I believe this removes one of their main adoption barriers going forward. The RECELL GO international rollout and PermeaDerm's positive…
benzinga.com TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14 TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.- benzinga.com BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11 BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
marketbeat.com Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft Avita Medical NASDAQ: RCEL presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness…
seekingalpha.com AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript- benzinga.com AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and…
globenewswire.com AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.- benzinga.com BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…- benzinga.com AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate.
benzinga.com AVITA Medical Q2 EPS $(0.25) Beats $(0.29) Estimate, Sales $21.702M Beat $20.167M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 34.21 percent increase over losses of…
benzinga.com Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include…
benzinga.com Why ServiceNow Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ServiceNow Inc (NOW) rose in pre-market trading after reporting better-than-expected Q2 results. LGCL, PLAG, EHGO, ZYBT, DOMO, AEHL, HYLN, LBGJ, RYAM gained. LESL, ZCMD, WHLR fell.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics…
- benzinga.com Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6 Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
- benzinga.com AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $82.258M Est AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $82.258 million estimate.
benzinga.com AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 33.96 percent increase over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com AVITA Medical Appoints Cary Vance President, CEO; Jan Stern As Board Chair, Effective Immediately AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive…
- benzinga.com AVITA Medical Announces Data From Cohealyx-I Multi-Center Trial Shows Reduction Of ~20 Days In Mean Time To Skin Grafting For Participants With Full-Thickness Wounds AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a…